Vanguard Group Inc. Increases Stock Position in Tarsus Pharmaceuticals, Inc. $TARS

Vanguard Group Inc. grew its stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 5.3% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,226,595 shares of the company’s stock after buying an additional 111,433 shares during the period. Vanguard Group Inc. owned 5.30% of Tarsus Pharmaceuticals worth $114,380,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in TARS. Wells Fargo & Company MN grew its stake in shares of Tarsus Pharmaceuticals by 44.1% during the 4th quarter. Wells Fargo & Company MN now owns 57,004 shares of the company’s stock valued at $3,156,000 after buying an additional 17,451 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter valued at $1,107,000. MetLife Investment Management LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 5.5% during the 4th quarter. MetLife Investment Management LLC now owns 22,678 shares of the company’s stock valued at $1,256,000 after acquiring an additional 1,174 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Tarsus Pharmaceuticals by 92.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 460,773 shares of the company’s stock valued at $25,514,000 after acquiring an additional 221,458 shares in the last quarter. Finally, Voya Investment Management LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 149.6% during the 4th quarter. Voya Investment Management LLC now owns 30,033 shares of the company’s stock valued at $1,663,000 after acquiring an additional 18,000 shares in the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on TARS. The Goldman Sachs Group lifted their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a “neutral” rating in a report on Monday, May 5th. Oppenheimer began coverage on shares of Tarsus Pharmaceuticals in a report on Monday, June 2nd. They set an “outperform” rating and a $75.00 target price on the stock. HC Wainwright upgraded shares of Tarsus Pharmaceuticals to a “buy” rating and set a $72.00 target price on the stock in a report on Tuesday, May 27th. Guggenheim lifted their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a “buy” rating in a report on Friday, May 2nd. Finally, Wall Street Zen lowered shares of Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals has a consensus rating of “Buy” and an average price target of $66.67.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS stock opened at $56.56 on Friday. Tarsus Pharmaceuticals, Inc. has a 12 month low of $25.14 and a 12 month high of $57.28. The company has a debt-to-equity ratio of 0.22, a current ratio of 5.26 and a quick ratio of 5.21. The firm has a market capitalization of $2.39 billion, a P/E ratio of -24.27 and a beta of 0.79. The company’s fifty day moving average price is $43.51 and its two-hundred day moving average price is $45.85.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.15). Tarsus Pharmaceuticals had a negative return on equity of 32.36% and a negative net margin of 31.13%.The firm had revenue of $102.66 million during the quarter, compared to analyst estimates of $95.81 million. On average, research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $50.00, for a total value of $300,000.00. Following the sale, the chief executive officer owned 818,106 shares in the company, valued at approximately $40,905,300. This represents a 0.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 8.97% of the company’s stock.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.